To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
The adjusted OR for receiving any treatment was 0.33 among patients living in an area where at least 20% of the population was below the poverty line.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Preclinical models suggested that PEGPH20, which degrades hyaluronan, would improve survival among patients with metastatic pancreatic adenocarcinoma.
Some patients diagnosed with HP or AP have a significantly increased risk of developing pancreatic cancer.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.
A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.
A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.
In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.
From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.
Previous genome-sequencing studies found that pancreatic cancer progression depends on 4 main driver genes — KRAS, CDKN2A, SMAD4, and TP53 — but there is a lack of research investigating the effect of these mutations on patient outcomes.
Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.
Pain management continues to be a challenge for patients with pancreatic cancer, though CPN may provide significant pain relief and an opportunity to reduce the amount of required narcotics.
In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.
Researchers evaluated whether adding apatorsen to a standard chemotherapy regimen would improve outcomes among patients with metastatic pancreatic cancer.
Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.
Researchers randomly assigned 140 patients with metastatic pancreatic cancer to receive eryaspase with standard of care FOLFOX or chemotherapy alone.
About 60% of Americans are deficient in magnesium, including up to 60% of patients who are critically ill.
At the median follow-up of 54 months, 177 (81%) of patients receiving gemcitabine plus erlotinib and 184 (85%) of patients receiving gemcitabine alone experienced disease recurrence.
Only 3 of 33 patients with susceptibility germline mutations had a family history of pancreatic cancer; this was true among 117 of the 818 other patients without a germline mutation.
Patients with advanced pancreatic cancer and ascites may benefit from regional radiofrequency thermotherapy in conjunction with systemic and intraperitoneal chemotherapy.
Treating physicians should watch for any suspicious signs of cancer after DM is diagnosed.
Aspirin may play a role in preventing and reducing cancer-specific mortality of particular cancers, including gastrointestinal cancers, pancreatic cancer, and prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy